2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
222
Carcinoma, Renal Cell
84
Liver Neoplasms
68
Neoplasms
53
Leukemia, Myeloid, Acute
37
Neoplasm Metastasis
34
Carcinoma, Non-Small-Cell Lung
33
Breast Neoplasms
29
Melanoma
24
Kidney Neoplasms
22
Pancreatic Neoplasms
16
Brain Neoplasms
15
Sarcoma
14
Prostatic Neoplasms
14
Lung Neoplasms
14
Thyroid Neoplasms
13
Recurrence
13
Glioblastoma
13
Colorectal Neoplasms
12
Carcinoma
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Urinary Bladder Neoplasms
8
Rectal Neoplasms
8
Ovarian Neoplasms
8
Myelodysplastic Syndromes
8
Multiple Myeloma
8
Gliosarcoma
8
Stomach Neoplasms
7
Colonic Neoplasms
7
Unspecified Adult Solid Tumor, Protocol Specific
6
Interventions
pertuzumab
1
pazopanib
1
enzalutamide
1
delta 24-sterol reductase
1
decitabine and cedazuridine drug combination
1
daratumumab
1
apalutamide
1
Validation Studies as Topic
1
Trastuzumab
1
Tape Recording
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Risk Assessment
1
Radiotherapy
1
Preoperative Exercise
1
Pilot Projects
1
Opdualag
1
Nutritional Support
1
Nivolumab
1
Injections, Subcutaneous
1
Focus Groups
1
Exercise
1
Ethanol
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Adiposity
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Patient Preference
×
Sorafenib
×
Clear all
NCT02616692
2017-09-27
HCC Patient Preferences in Japan
Bayer
Completed
120 enrolled